Drug Trial Radar · NCT03739814
Inotuzumab Ozogamicin and Blinatumomab With or Without Ponatinib in Treating Patients With Newly Diagnosed, Recurrent, or Refractory CD22-Positive B-Lineage Acute Lymphoblastic Leukemia
Last checked: Nov 20, 2026Latest source record: Nov 18, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Recruiting
Enrollment
84
Planned (sponsor's estimate)
Start
May 8, 2019
Primary completion
Feb 1, 2027
Study completion Feb 1, 2027
Sponsor
- Lead sponsor
- National Cancer Institute (NCI)NIH
- Sponsor type
- NIH
- First posted
- Nov 14, 2018
Design
- Study type
- Interventional
- Phase
- Phase 2
- Allocation
- Non randomized
- Model
- Parallel
- Masking
- None
- Primary purpose
- Treatment
- FDA-regulated drug
- Yes
- Who can join
- All sexes, from 18 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
This phase II trial studies how well inotuzumab ozogamicin and blinatumomab with or without ponatinib work in treating patients with CD22-positive B-lineage acute lymphoblastic leukemia that is newly diagnosed, has come back after a period of improvement (recurrent), or does not respond to treatment (refractory). Inotuzumab ozogamicin is a monoclonal antibody, called inotuzumab, linked to a chemotherapy drug, called ozogamicin. Inotuzumab is a form of targeted therapy because it attaches to specific molecules (receptors) on the surface of cancer cells, known as CD22 receptors, and delivers ozogamicin to kill them. Blinatumomab is a monoclonal antibody that may interfere with the ability of cancer cells to grow and spread. A monoclonal antibody is a type of protein that can bind to certain targets in the body, such as molecules that cause the body to make an immune response (antigens). Ponatinib may stop the growth of cancer cells by blocking some of the enzymes needed for cell growth. Giving inotuzumab ozogamicin and blinatumomab with or without ponatinib may be effective in treating patients with newly diagnosed, recurrent or refractory CD22 positive B-lineage acute lymphoblastic leukemia.
Conditions
- B Acute Lymphoblastic Leukemia, Philadelphia Chromosome Negative
- Recurrent B Acute Lymphoblastic Leukemia
- Refractory B Acute Lymphoblastic Leukemia
Interventions
Biospecimen CollectionProcedure
Undergo blood sample and cerebrospinal fluid collection
BlinatumomabBiological
Given IV
Bone Marrow AspirationProcedure
Undergo bone marrow aspiration
Bone Marrow BiopsyProcedure
Undergo bone marrow biopsy
Inotuzumab OzogamicinBiological
Given IV
Lumbar PunctureProcedure
Undergo lumbar puncture
PonatinibDrug
Given PO
Primary outcomes
What the sponsor says the trial is designed to measure.
- Event-free survivalTime frame: At 1 year
- Completion of protocol treatment (cohort 3)Time frame: Up to 10 years
Locations
285 sites in 2 countries. Site status is shown where the registry gives one.
University of Alabama at Birmingham Cancer Center
Birmingham, Alabama · Active not recruiting
Anchorage Associates in Radiation Medicine
Anchorage, Alaska · Suspended
Anchorage Radiation Therapy Center
Anchorage, Alaska · Suspended
Alaska Breast Care and Surgery LLC
Anchorage, Alaska · Suspended
Alaska Oncology and Hematology LLC
Anchorage, Alaska · Suspended
Alaska Women's Cancer Care
Anchorage, Alaska · Suspended
Anchorage Oncology Centre
Anchorage, Alaska · Suspended
Katmai Oncology Group
Anchorage, Alaska · Suspended
Providence Alaska Medical Center
Anchorage, Alaska · Suspended
Kingman Regional Medical Center
Kingman, Arizona · Suspended
Mercy Hospital Fort Smith
Fort Smith, Arkansas · Suspended
PCR Oncology
Arroyo Grande, California · Suspended
Providence Saint Joseph Medical Center/Disney Family Cancer Center
Burbank, California · Suspended
Community Cancer Institute
Clovis, California · Active not recruiting
University Oncology Associates
Clovis, California · Active not recruiting
City of Hope Comprehensive Cancer Center
Duarte, California · Recruiting
UCI Health - Chao Family Comprehensive Cancer Center and Ambulatory Care
Irvine, California · Recruiting
UC San Diego Moores Cancer Center
La Jolla, California · Recruiting
UC Irvine Health/Chao Family Comprehensive Cancer Center
Orange, California · Recruiting
Stanford Cancer Institute Palo Alto
Palo Alto, California · Active not recruiting
Beebe Medical Center
Lewes, Delaware · Suspended
Beebe South Coastal Health Campus
Millville, Delaware · Suspended
Delaware Clinical and Laboratory Physicians PA
Newark, Delaware · Suspended
Helen F Graham Cancer Center
Newark, Delaware · Recruiting
Medical Oncology Hematology Consultants PA
Newark, Delaware · Recruiting
Christiana Care Health System-Christiana Hospital
Newark, Delaware · Suspended
Beebe Health Campus
Rehoboth Beach, Delaware · Suspended
TidalHealth Nanticoke / Allen Cancer Center
Seaford, Delaware · Suspended
Christiana Care Health System-Wilmington Hospital
Wilmington, Delaware · Suspended
MedStar Georgetown University Hospital
Washington D.C., District of Columbia · Recruiting
Holy Cross Hospital
Fort Lauderdale, Florida · Suspended
Jupiter Medical Center
Jupiter, Florida · Recruiting
Emory University Hospital/Winship Cancer Institute
Atlanta, Georgia · Recruiting
Emory Saint Joseph's Hospital
Atlanta, Georgia · Recruiting
Saint Luke's Cancer Institute - Boise
Boise, Idaho · Suspended
Saint Luke's Cancer Institute - Fruitland
Fruitland, Idaho · Suspended
Saint Luke's Cancer Institute - Meridian
Meridian, Idaho · Suspended
Saint Alphonsus Cancer Care Center-Nampa
Nampa, Idaho · Recruiting
Saint Luke's Cancer Institute - Nampa
Nampa, Idaho · Suspended
Saint Luke's Cancer Institute - Twin Falls
Twin Falls, Idaho · Suspended
Showing 40 of 285 sites, US sites first. The full list is on the registry record.
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.